Vicky Makker
维基·马克尔
MD, MAS
Medical Oncologist; Associate Attending Physician, Gynecologic Medical Oncology肿瘤内科医生；妇科肿瘤内科副主治医师
👥Biography 个人简介
Vicky Makker, MD, MAS is a leading gynecologic oncologist at MSK who established lenvatinib plus pembrolizumab (Study 309/KEYNOTE-775) as standard of care for advanced endometrial cancer, and characterized pembrolizumab activity in MSI-H/dMMR tumors via KEYNOTE-158.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Lenvatinib + Pembrolizumab in Advanced Endometrial Cancer
Led Study 309/KEYNOTE-775, demonstrating superior PFS and OS with lenvatinib plus pembrolizumab vs chemotherapy, leading to FDA approval in 2021 for advanced endometrial cancer.
KEYNOTE-158 Pembrolizumab in MSI-H/dMMR Endometrial Cancer
Key investigator for KEYNOTE-158 cohort evaluating pembrolizumab in MSI-H/dMMR endometrial cancer, supporting tumor-agnostic FDA approval of pembrolizumab for MSI-H solid tumors.
Representative Works 代表性著作
Lenvatinib plus pembrolizumab for advanced endometrial cancer (Study 309/KEYNOTE-775)
New England Journal of Medicine (2022)
Phase III trial showing lenvatinib+pembrolizumab improved PFS and OS vs chemotherapy in advanced endometrial cancer, establishing a new standard of care.
Pembrolizumab in patients with MSI-H/dMMR endometrial cancer (KEYNOTE-158)
Journal of Clinical Oncology (2019)
Demonstrated durable antitumor activity of pembrolizumab in MSI-H/dMMR endometrial cancer, supporting accelerated FDA approval.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 维基·马克尔 的研究动态
Follow Vicky Makker's research updates
留下邮箱，当我们发布与 Vicky Makker（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment